Fundies. English
GALECTIN THERAPEUTICS INC
EDGAR126 filing records in this dataset, filed from 2001-09-07 to 2026-08-14. Reported financial figures are available; chart coverage varies by period.
- Cash and cash equivalents
- 13.3 million USD Source
Exact value
13300000 USD
- Long-term debt including current maturities
- Not available
- Shares outstanding
- 66.3 million shares Source
Exact value
66311910 shares
Reported share-count change
3.51% · 2.25 million shares
Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.
Includes later revisions to earlier periods. Annual charts exclude incomplete years.
Latest filing recorded: 2026-08-14.
Financial data available through: 2025-12-31.
Coverage by financial measure
- revenue: No compatible figures in this window
- Operating income: 8 of 11 periods available· newest 2025-12-31
- Net income: 8 of 11 periods available· newest 2025-12-31
- Operating cash flow: 8 of 11 periods available· newest 2025-12-31
- Capital expenditure: 1 of 11 periods available· newest 2015-12-31
- Total assets: 8 of 11 periods available· newest 2025-12-31
- Total liabilities: 8 of 11 periods available· newest 2025-12-31
- Current assets: 8 of 11 periods available· newest 2025-12-31
- Current liabilities: 8 of 11 periods available· newest 2025-12-31
- Cash and cash equivalents: 8 of 11 periods available· newest 2025-12-31
- long term debt: No compatible figures in this window
- Shares outstanding: 8 of 11 periods available· newest 2025-12-31
Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.
What changed year over year
Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.
Net income
+USD 16.21 millionPrior period
−USD 47.05 million
–
Current period
−USD 30.84 million
–
Exact inputs and evidence
-30836000 − -47047000 = 16211000 USD
-47047000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source-30836000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 17.9 millionPrior period
−USD 41.8 million
–
Current period
−USD 23.9 million
–
Exact inputs and evidence
-23900000 − -41800000 = 17900000 USD
-41800000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source-23900000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Comparable inputs unavailable for: Revenue, Capital expenditure.
Where revenue goes
How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.
Revenue is not reported for this company, so its costs cannot be shown as a share of it.
Growth
Sales over time and how quickly they are changing.
Revenue
Revenue reported for each complete financial period.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Revenue growth
Change in revenue from the same financial period one year earlier.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Profit and cash
How much revenue becomes profit, and how much cash operations generate.
Profit margins
Operating income, net income and free cash flow as a share of revenue.
- Operating margin
- Net margin
- Free cash flow margin
Values and sources
| Period | Series | Value | Source evidence |
|---|
Operating cash flow
Cash generated by the company’s normal business operations.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Free cash flow
Operating cash flow minus capital expenditure for the same period and unit.
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|
Balance sheet
Liabilities and short-term ability to meet obligations at each period end.
Liabilities to assets
Total liabilities as a share of total assets.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Current assets to current liabilities
Current assets divided by current liabilities.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Cash generation
Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.
| Period | Net income | Operating cash flow | Capital expenditure | Free cash flow |
|---|---|---|---|---|
| 2015 2015-01-01 – 2015-12-31 | −USD 20.03 million Exact valueExact value: -20027000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 16.98 million Exact valueExact value: -16983000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 0 Exact valueExact value: 0 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 16.98 million Calculation and evidence-16983000 − 0 USD Exact free cash flow: -16983000 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2016 2016-01-01 – 2016-12-31 | −USD 21.44 million Exact valueExact value: -21436000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 16.41 million Exact valueExact value: -16409000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2017 2017-01-01 – 2017-12-31 | −USD 16.24 million Exact valueExact value: -16235000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 15.89 million Exact valueExact value: -15892000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2018 2018-01-01 – 2018-12-31 | −USD 13.9 million Exact valueExact value: -13900000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 10.18 million Exact valueExact value: -10179000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2019 2019-01-01 – 2019-12-31 | −USD 13.29 million Exact valueExact value: -13294000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 10.85 million Exact valueExact value: -10848000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2020 2020-01-01 – 2020-12-31 | −USD 23.47 million Exact valueExact value: -23465000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 20.6 million Exact valueExact value: -20601000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2024 2024-01-01 – 2024-12-31 | −USD 47.05 million Exact valueExact value: -47047000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 41.8 million Exact valueExact value: -41800000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2025 2025-01-01 – 2025-12-31 | −USD 30.84 million Exact valueExact value: -30836000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 23.9 million Exact valueExact value: -23900000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.
Dataset coverage and company identifiers
Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.
126 filings · 3,444 latest values · 3,444 originally reported values
Dataset published . Source filing dates and reporting periods are shown separately.
Identifiers: 0001133416, 1133416, GALT, edgar:1133416
Also known as GALECTIN THERAPEUTICS INC, GALECTIN THERAPEUTICS INC., Galectin Therapeutics, Inc., PRO PHARMACEUTICALS INC